Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 22, 2026, 9:05 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 27 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Paclitaxel Induced Neuropathy Clear all
Completed Not applicable Interventional

Acupuncture to Reduce Chemotherapy-induced Peripheral Neuropathy Severity During Neoadjuvant or Adjuvant Weekly Paclitaxel Chemotherapy in Breast Cancer Patients

NCT02364726
View directory record Official record
Conditions
Breast Cancer, Peripheral Neuropathy
Interventions
Acupuncture, Neuropathic Pain Scale (NPS) questionnaire, FACT/GOG-Ntx questionnaire
Procedure · Behavioral
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
21 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2023
U.S. locations
2
States / cities
Harrison, New York • New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 21, 2023 · Synced Jul 22, 2026, 9:05 PM EDT
Completed Phase 1 Interventional

Calcium and Magnesium Infusion for the Prevention of Taxane Induced Neuropathy

NCT01682499
View directory record Official record
Conditions
Paclitaxel-induced Neuropathy
Interventions
calcium gluconate and magnesium sulfate
Drug
Lead sponsor
Beth Israel Medical Center
Other
Eligibility
21 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
3
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 24, 2014 · Synced Jul 22, 2026, 9:05 PM EDT
Completed Phase 3 Interventional Results available

Glutathione in Preventing Peripheral Neuropathy Caused by Paclitaxel and Carboplatin in Patients With Ovarian Cancer, Fallopian Tube Cancer, and/or Primary Peritoneal Cancer

NCT02311907
View directory record Official record
Conditions
Chemotherapeutic Agent Toxicity, Neuropathy, Neurotoxicity Syndrome, Pain, Stage IIIA Fallopian Tube Cancer, Stage IIIA Ovarian Cancer, Stage IIIA Primary Peritoneal Cancer, Stage IIIB Fallopian Tube Cancer, Stage IIIB Ovarian Cancer, Stage IIIB Primary Peritoneal Cancer, Stage IIIC Fallopian Tube Cancer, Stage IIIC Ovarian Cancer, Stage IIIC Primary Peritoneal Cancer, Stage IV Fallopian Tube Cancer, Stage IV Ovarian Cancer, Stage IV Primary Peritoneal Cancer
Interventions
Carboplatin, Glutathione, Laboratory Biomarker Analysis, Paclitaxel, Placebo, Quality-of-Life Assessment
Drug · Other
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
195 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
390
States / cities
Mobile, Alabama • Fairbanks, Alaska • Scottsdale, Arizona + 259 more
Source: ClinicalTrials.gov public record
Updated Feb 22, 2017 · Synced Jul 22, 2026, 9:05 PM EDT
Active, not recruiting Phase 2 Interventional

A Study of Topical Pirenzepine or Placebo in Oncology Patients With Chemotherapy Induced Peripheral Neuropathy

NCT05488873
View directory record Official record
Conditions
Chemotherapy-induced Peripheral Neuropathy
Interventions
WST-057 Active, Placebo
Drug
Lead sponsor
WinSanTor, Inc
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Charlotte, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 21, 2024 · Synced Jul 22, 2026, 9:05 PM EDT
Completed Not applicable Interventional

Chemotherapy Induced Peripheral Neuropathy (CIPN)

NCT03272919
View directory record Official record
Conditions
Chemotherapy-induced Peripheral Neuropathy
Interventions
Arm 1: Investigational INF, Arm 2: standardized muscle stretching and strength
Other
Lead sponsor
Loma Linda University
Other
Eligibility
18 Years and older · Female only
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
1
States / cities
Loma Linda, California
Source: ClinicalTrials.gov public record
Updated May 9, 2023 · Synced Jul 22, 2026, 9:05 PM EDT
Terminated Not applicable Interventional Results available

The Efficacy of Acupuncture in Treating Chemotherapy Side Effects in Breast Cancer Patients

NCT01996410
View directory record Official record
Conditions
Breast Cancer Stages I Through III
Interventions
Acupuncture
Device
Lead sponsor
OhioHealth
Other
Eligibility
18 Years and older · Female only
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 20, 2016 · Synced Jul 22, 2026, 9:05 PM EDT
Terminated Phase 2 Interventional Results available

NR in Chemo-induced Peripheral Neuropathy

NCT03642990
View directory record Official record
Conditions
Chemotherapy-induced Peripheral Neuropathy, Breast Cancer Metastatic, Platinum-resistant Recurrent Ovarian Cancer, Head and Neck Cancer Stage IV, Endometrial Cancer Stage IV
Interventions
Nicotinamide Riboside
Drug
Lead sponsor
Donna Hammond, PhD
Other
Eligibility
18 Years to 85 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
2
States / cities
Iowa City, Iowa • Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 11, 2023 · Synced Jul 22, 2026, 9:05 PM EDT
Recruiting No phase listed Observational

Whole Exome Sequencing in Finding Causative Variants in Germline DNA Samples From Patients With Peripheral Neuropathy Receiving Paclitaxel for Breast Cancer

NCT02610439
View directory record Official record
Conditions
Breast Carcinoma, Neuropathy
Interventions
Laboratory Biomarker Analysis
Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Not listed
Enrollment
575 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2100
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 26, 2026 · Synced Jul 22, 2026, 9:05 PM EDT
Completed Phase 2 Interventional Results available

Minocycline Hydrochloride in Reducing Chemotherapy-Induced Peripheral Neuropathy and Acute Pain in Patients With Breast Cancer Undergoing Treatment With Paclitaxel

NCT02297412
View directory record Official record
Conditions
Acute Pain, Breast Carcinoma, Peripheral Neuropathy
Interventions
Minocycline Hydrochloride, Placebo, Quality-of-Life Assessment, Questionnaire Administration
Drug · Other
Lead sponsor
Academic and Community Cancer Research United
Other
Eligibility
18 Years and older
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
12
States / cities
Pismo Beach, California • Normal, Illinois • Urbana, Illinois + 9 more
Source: ClinicalTrials.gov public record
Updated Jan 30, 2022 · Synced Jul 22, 2026, 9:05 PM EDT
Completed No phase listed Observational

Objective Evaluation of Paclitaxel/Docetaxel-induced Neuropathy in Breast Cancer Patients

NCT03872141
View directory record Official record
Conditions
Breast Cancer, Chemotherapy Induced Peripheral Neuropathy, Paclitaxel Induced Neuropathy
Interventions
Quantitative measures of reduction in Chemotherapy Induced Neuropathy (CIPN) and Cognitive Impairment (CICI) in patients with stage I-III breast cancer
Diagnostic Test
Lead sponsor
Yale University
Other
Eligibility
18 Years to 70 Years · Female only
Enrollment
13 participants
Timeline
2017 – 2021
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated May 2, 2021 · Synced Jul 22, 2026, 9:05 PM EDT
Completed Phase 2 Interventional

Amifostine in Treating Peripheral Neuropathy Caused by Paclitaxel in Patients With Solid Tumors

NCT00078845
View directory record Official record
Conditions
Breast Cancer, Lung Cancer, Neurotoxicity, Ovarian Cancer, Prostate Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
Amifostine
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
15
States / cities
Decatur, Illinois • Urbana, Illinois • Wichita, Kansas + 12 more
Source: ClinicalTrials.gov public record
Updated Oct 16, 2012 · Synced Jul 22, 2026, 9:05 PM EDT
Recruiting Phase 2 Interventional

Cryocompression With or Without Cilostazol for the Prevention of Paclitaxel-induced Neuropathy in Patients With Gynecological Cancers

NCT06492070
View directory record Official record
Conditions
Cervical Carcinoma, Fallopian Tube Carcinoma, Malignant Solid Neoplasm, Malignant Uterine Neoplasm, Ovarian Carcinoma, Primary Peritoneal Carcinoma, Vulvar Carcinoma
Interventions
Best Practice, Cilostazol, Cryocompression Therapy, Paclitaxel, Quality-of-Life Assessment
Other · Drug · Device
Lead sponsor
Emory University
Other
Eligibility
18 Years and older · Female only
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
3
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Aug 26, 2025 · Synced Jul 22, 2026, 9:05 PM EDT
Completed Not applicable Interventional Results available

Hand Therapy Intervention Versus Traditional Occupational Therapy to Prevent Chemotherapy Induced Peripheral Neuropathy

NCT05374876
View directory record Official record
Conditions
Adenocarcinoma of Pancreas
Interventions
Hand Therapy Until CIPN, Traditional Occupational Therapy (TOT)
Other
Lead sponsor
HonorHealth Research Institute
Other
Eligibility
18 Years and older
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
1
States / cities
Scottsdale, Arizona
Source: ClinicalTrials.gov public record
Updated Jul 7, 2026 · Synced Jul 22, 2026, 9:05 PM EDT
Active, not recruiting Phase 2 Interventional Results available

Taxane and Taxane-Induced Peripheral Neuropathy in African American Patients With Stage I-III Breast Cancer

NCT04001829
View directory record Official record
Conditions
Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage IA Breast Cancer AJCC v8, Anatomic Stage IB Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIA Breast Cancer AJCC v8, Anatomic Stage IIB Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIIB Breast Cancer AJCC v8, Anatomic Stage IIIC Breast Cancer AJCC v8, Invasive Breast Carcinoma, Prognostic Stage I Breast Cancer AJCC v8, Prognostic Stage IA Breast Cancer AJCC v8, Prognostic Stage IB Breast Cancer AJCC v8, Prognostic Stage II Breast Cancer AJCC v8, Prognostic Stage IIA Breast Cancer AJCC v8, Prognostic Stage IIB Breast Cancer AJCC v8, Prognostic Stage III Breast Cancer AJCC v8, Prognostic Stage IIIA Breast Cancer AJCC v8, Prognostic Stage IIIB Breast Cancer AJCC v8, Prognostic Stage IIIC Breast Cancer AJCC v8
Interventions
Docetaxel, Paclitaxel, Quality-of-Life Assessment, Questionnaire Administration
Drug · Other
Lead sponsor
ECOG-ACRIN Cancer Research Group
Network
Eligibility
18 Years and older · Female only
Enrollment
249 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
485
States / cities
Birmingham, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 310 more
Source: ClinicalTrials.gov public record
Updated Jul 5, 2026 · Synced Jul 22, 2026, 9:05 PM EDT
Terminated Not applicable Interventional

Acupuncture in Treating Nerve Pain in Patients With Stage I, Stage II, or Stage III Breast Cancer Who Are Receiving Paclitaxel

NCT01050075
View directory record Official record
Conditions
Breast Cancer, Stage I Breast Cancer, Stage II Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer
Interventions
acupuncture therapy, questionnaire administration, management of therapy complications
Other
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
2
States / cities
Duarte, California • Pasadena, California
Source: ClinicalTrials.gov public record
Updated Nov 5, 2017 · Synced Jul 22, 2026, 9:05 PM EDT
Completed Phase 1 Interventional Results available

Nilotinib in Preventing Paclitaxel-Induced Peripheral Neuropathy in Patients With Stage I-III Breast Cancer

NCT04205903
View directory record Official record
Conditions
Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage IA Breast Cancer AJCC v8, Anatomic Stage IB Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIA Breast Cancer AJCC v8, Anatomic Stage IIB Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIIB Breast Cancer AJCC v8, Anatomic Stage IIIC Breast Cancer AJCC v8, Prognostic Stage I Breast Cancer AJCC v8, Prognostic Stage IA Breast Cancer AJCC v8, Prognostic Stage IB Breast Cancer AJCC v8, Prognostic Stage II Breast Cancer AJCC v8, Prognostic Stage IIA Breast Cancer AJCC v8, Prognostic Stage IIB Breast Cancer AJCC v8, Prognostic Stage III Breast Cancer AJCC v8, Prognostic Stage IIIA Breast Cancer AJCC v8, Prognostic Stage IIIB Breast Cancer AJCC v8, Prognostic Stage IIIC Breast Cancer AJCC v8
Interventions
Nilotinib, Nilotinib Hydrochloride Monohydrate, Paclitaxel, Questionnaire Administration
Drug · Other
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 28, 2025 · Synced Jul 22, 2026, 9:05 PM EDT
Terminated Not applicable Interventional Results available

Acupuncture Treatment of Chemotherapy-Induced Peripheral Neuropathy in Women

NCT04067544
View directory record Official record
Conditions
Chemotherapy-induced Peripheral Neuropathy, Breast Cancer Female, Gynecologic Cancer
Interventions
Acupuncture
Device
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older · Female only
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Apr 5, 2025 · Synced Jul 22, 2026, 9:05 PM EDT
Active, not recruiting No phase listed Observational Accepts healthy volunteers

Assessment of Paclitaxel-Induced Neuropathy

NCT01953159
View directory record Official record
Conditions
Cancer, Breast Cancer, Ovarian Cancer
Interventions
Blood Collection, Patient Questionnaires
Other
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older · Female only
Enrollment
43 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2027
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 7, 2025 · Synced Jul 22, 2026, 9:05 PM EDT
Terminated Not applicable Interventional

Investigating the Preventative Ability of Massage Therapy on Paclitaxel Induced Peripheral Neuropathy

NCT03557554
View directory record Official record
Conditions
Breast Cancer, Neuropathy, Neuropathy;Peripheral
Interventions
Massage
Other
Lead sponsor
Bryan Schneider
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Aug 25, 2019 · Synced Jul 22, 2026, 9:05 PM EDT
Terminated Not applicable Interventional

The Use of Cryotherapy to Prevent Paclitaxel-induced Peripheral Neuropathy and Nail Changes in Women With Breast Cancer

NCT04558034
View directory record Official record
Conditions
Cryotherapy Effect, Peripheral Neuropathy, Nail Toxicity
Interventions
cryotherapy
Other
Lead sponsor
Parkview Health
Other
Eligibility
18 Years and older · Female only
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Fort Wayne, Indiana
Source: ClinicalTrials.gov public record
Updated Mar 7, 2021 · Synced Jul 22, 2026, 9:05 PM EDT
Terminated Not applicable Interventional

Cryotherapy in Preventing Peripheral Neuropathy and Nail Toxicity in Patients With Breast Cancer Who Are Receiving Paclitaxel

NCT01243541
View directory record Official record
Conditions
Chemotherapeutic Agent Toxicity, Pain, Peripheral Neuropathy, Recurrent Breast Cancer, Stage IA Breast Cancer, Stage IB Breast Cancer, Stage II Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer, Therapy-related Toxicity
Interventions
cryotherapy, questionnaire administration, quality-of-life assessment, management of therapy complications, assessment of therapy complications
Procedure · Other
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older · Female only
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Aug 19, 2019 · Synced Jul 22, 2026, 9:05 PM EDT
Completed Not applicable Interventional

Omega-3 Fatty Acid in Treating Pain in Patients With Breast or Ovarian Cancer Receiving Paclitaxel

NCT01821833
View directory record Official record
Conditions
Breast Cancer, Ovarian Neoplasm, Pain
Interventions
Omega-3 fatty acid, Placebo, Paclitaxel
Dietary Supplement · Drug
Lead sponsor
New Mexico Cancer Research Alliance
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
2
States / cities
Albuquerque, New Mexico
Source: ClinicalTrials.gov public record
Updated Oct 4, 2022 · Synced Jul 22, 2026, 9:05 PM EDT
Recruiting Phase 2 Interventional

Tart Cherry Juice as a Dietary Supplement for the Prevention of Paclitaxel-Induced Neuropathy

NCT06268665
View directory record Official record
Conditions
Breast Cancer, Breast Cancer Stage I, Breast Cancer Stage II, Breast Cancer Stage III, Breast Cancer Stage IV, Invasive Breast Cancer, Ovarian Cancer, Ovarian Cancer Stage 1, Ovarian Cancer Stage II, Ovarian Cancer Stage III, Ovarian Cancer Stage IV, Ovarian Cancer Stage IA, Ovarian Cancer Stage IB, Ovarian Cancer Stage IC, Ovarian Cancer Stage 2, Ovarian Cancer Stage 3, Ovarian Cancer Stage IIIb, Ovarian Cancer Stage IIIC, Breast Cancer Stage IIIA, Breast Cancer Invasive, Breast Cancer, Stage IA, Breast Cancer, Stage IB, Breast Cancer Stage IIA, Breast Cancer Stage IIB, Breast Cancer Stage IIIB, Breast Cancer Stage IIIc, Cancer, Breast, Tumors, Breast, Mammary Cancer, Mammary Carcinoma, Breast Carcinoma, Breast Neoplasm, Malignant Breast Neoplasm, Malignant Tumor of Breast, Cancer of Ovary, Ovary Cancer, Ovary Neoplasm
Interventions
Tart Cherry Juice
Drug
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years and older
Enrollment
86 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Mar 3, 2026 · Synced Jul 22, 2026, 9:05 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Early Detection of Taxane-Induced Neuropathy in Women With Breast Cancer

NCT02549534
View directory record Official record
Conditions
Peripheral Neuropathy
Interventions
Axon Reflexes, Axon Flares, Self-Reported Signs & Symptoms of CIPN
Procedure
Lead sponsor
Indiana University
Other
Eligibility
18 Years to 85 Years · Female only
Enrollment
29 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
2
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Oct 26, 2017 · Synced Jul 22, 2026, 9:05 PM EDT